Posted by Michael Wonder on 04 Feb 2025
Durvalumab with tremelimumab for the first-line treatment of patients with advanced or unresectable hepatocellular carcinoma
4 February 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of durvalumab in combination with tremelimumab in the NHS in England.
For the time being, the combination of durvalumab and tremelimumab is not recommended for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma.
